^
Association details:
Biomarker:NCR3LG1 underexpression + TMB-L
Cancer:Melanoma
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Correlation of low B7-H6 expression with efficacy of immunotherapy inpatients with melanoma.

Published date:
05/25/2023
Excerpt:
Herein, we used the data from a clinically annotated cohort of melanoma patients treated with ICI to analyze the influence of B7-H6 expression on immunotherapy....TMB-H (top 25%) (p value = 0.051) and B7-H6 (p value = 0.051) low expression were associated with a better OS. Then the patients were divided into four groups according to the TMB and B7-H6 expression and analyzed the difference in the four groups. The results showed that in patients with TMB-L, B7-H6 low group had significant better OS than the B7-H6 high group (p value = 0.032).
DOI:
10.1200/JCO.2023.41.16_suppl.e21556